文献速递乳腺癌支持与姑息治疗

阴道睾酮乳膏与雌二醇阴道环用于接受芳香化酶抑制剂治疗的早期乳腺癌女性阴道干燥或性欲减退:一项随机临床试验

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

该随机非比较设计研究纳入76名接受芳香化酶抑制剂、有阴道干燥或性欲减退等症状的绝经后激素受体阳性早期乳腺癌患者,随机接受12周阴道睾酮乳膏或雌二醇阴道环(7.5 μg/d)。阴道环组无持续性雌二醇升高,阴道睾酮乳膏组有4/34(12%)出现持续性升高;两组阴道萎缩及性功能均改善。

要点

  • 阴道环组无持续性雌二醇升高,阴道睾酮乳膏组4/34(12%)出现持续性升高。
  • 一过性雌二醇升高见于阴道环组4/35(11%)和阴道睾酮乳膏组4/34(12%)。
  • 两组阴道萎缩、性兴趣及性功能障碍均改善。

核心结论

  • 在接受芳香化酶抑制剂的绝经后早期乳腺癌患者中,阴道环或阴道睾酮乳膏治疗12周均达到主要安全终点。
  • 基线雌二醇升高常见,使该评估复杂化。
  • 阴道萎缩、性兴趣及性功能障碍均改善。
  • 需要进一步研究以了解该背景下雌二醇的变异性。

研究设计与样本

  • 随机非比较设计,纳入76名签署知情同意、平均(范围)年龄56(37-78)岁的绝经后激素受体阳性I至III期乳腺癌正在服用芳香化酶抑制剂且有自报阴道干燥、性交困难或性欲减退的女性。
  • 75名开始治疗,69名完成12周治疗;随机接受12周阴道睾酮乳膏或雌二醇阴道环(7.5 μg/d)。
  • 基线及第4、12周采用液相色谱-串联质谱法测定雌二醇,基线及第4周测定促卵泡激素;基线和第12周完成妇科检查及性生活质量问卷。

主要发现

  • 基线雌二醇均值(范围)为20(<2至127)pg/mL;76名女性中28名(37%)基线雌二醇高于绝经后范围(>10 pg/mL)。
  • 持续性雌二醇升高在阴道环组为0例,在阴道睾酮乳膏组为4/34(12%)。
  • 一过性雌二醇升高在阴道环组为4/35(11%),在阴道睾酮乳膏组为4/34(12%)。
  • 所有患者的阴道萎缩、性兴趣及性功能障碍均改善。

关键数值与推荐

  • 干预被认为不安全的标准为:超过25%的患者在开始治疗后连续两次至少间隔2周的检测中雌二醇大于10 pg/mL且较基线至少高10 pg/mL。
  • 持续性雌二醇升高:阴道环组0例,阴道睾酮乳膏组4/34(12%)。
  • 一过性雌二醇升高:阴道环组4/35(11%),阴道睾酮乳膏组4/34(12%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以了解该背景下雌二醇的变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. OBJECTIVE: To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI. Intervention was considered unsafe if more than 25% of patients had persistent elevation in estradiol (E2), defined as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3.671) and at least 10 pg/mL above baseline after treatment initiation on 2 consecutive tests at least 2 weeks apart. DESIGN, SETTING, AND PARTICIPANTS: Postmenopausal (PM) women with hormone receptor (HR)-positive stage I to III BC taking AIs with self-reported vaginal dryness, dyspareunia, or decreased libido were randomized to 12 weeks of IVT or an estradiol vaginal ring. Estradiol was measured at baseline and weeks 4 and 12 using a commercially available liquid chromatography and tandem mass spectrometry assay; follicle-stimulating hormone levels were measured at baseline and week 4. Gynecologic examinations and sexual quality-of-life questionnaires were completed at baseline and week 12. This randomized noncomparative design allowed safety evaluation of 2 interventions concurrently in the same population of patients, reducing the possibility of E2 assay variability over time and between the 2 interventions. MAIN OUTCOMES AND MEASURES: The primary objective of this trial was to evaluate safety of IVT or an estradiol vaginal ring in patients with early-stage BC receiving an AI; secondary objectives included evaluation of adverse events, changes in sexual quality of life using the Cancer Rehabilitation Evaluation System sexuality subscales, changes in vaginal atrophy using a validated 4-point scale, and comparison of E2 levels. RESULTS: Overall, 76 women signed consent (mean [range] age, 56 [37-78] years), 75 started treatment, and 69 completed 12 weeks of treatment. Mean (range) baseline E2 was 20 (<2 to 127) pg/mL. At baseline, E2 was above the postmenopausal range (>10 pg/mL) in 28 of 76 women (37%). Persistent E2 elevation was observed in none with a vaginal ring and in 4 of 34 women (12%) with IVT. Transient E2 elevation was seen in 4 of 35 (11%) with a vaginal ring and in 4 of 34 (12%) with IVT. Vaginal atrophy and sexual interest and dysfunction improved for all patients. CONCLUSIONS AND RELEVANCE: In PM women with early-stage BC receiving AIs, treatment with a vaginal ring or IVT over 12 weeks met the primary safety end point. Baseline elevation in E2 was common and complicates this assessment. Vaginal atrophy, sexual interest, and sexual dysfunction were improved. Further study is required to understand E2 variability in this setting. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00698035.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Melisko ME, Goldman ME, Hwang J, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 27832260. doi:10.1001/jamaoncol.2016.3904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。